Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Liye Chen has been awarded a Versus Arthritis five-year career development fellowship to identify and validate new T cell therapeutic targets in ankylosing spondylitis (AS).

AS is a painful and progressive form of inflammatory arthritis, affecting around 200,000 people in the UK. The disease causes inflammation in the spine and other joints, leading to pain, stiffness, and fatigue.

Although treatment for AS has greatly improved in the past decade, a definitive cure has not yet been found and many patients suffer persistent symptoms or unacceptable side effects from current therapies.

AS has a strong genetic basis, with over 100 genetic variations linked to the condition. Through bioinformatics integration of genetic data and gene expression profiles of T cells from blood and joint fluid from patients with AS, the innovative programme of research will allow Dr Chen to identify novel T cell regulators in AS which are potential therapeutic targets.

Dr Chen says: “It’s very exciting to be able to look at AS through different lenses and bring such cutting-edge technologies to the table. The integration of multiple datasets (GWAS, eQTL and RNA sequencing of patient-derived T cells) and functional screen of identified genes using disease relevant cellular assays will allow us to identify genes that contribute to AS pathogenesis much faster than currently possible.”

Once the novel AS T cell regulators have been identified and validated in cellular assays, Dr Chen will focus on the most promising and novel regulators for their functional mechanisms and therapeutic potentials.

“I’m very grateful to Versus Arthritis for granting me the opportunity to contribute to such an important field or research, aiding their aims of finding a cure for major forms of arthritis and helping thousands of patients worldwide.” concludes Dr Chen.

Funded by

Versus Arthritis logo

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.